Protozoal and anaerobic bacterial deoxyribonucleic acid (DNA)

Protozoal and anaerobic bacterial DNA is the primary molecular target for the nitroimidazole class of antimicrobial agents, such as metronidazole and tinidazole. These organisms possess unique metabolic pathways, specifically the pyruvate:ferredoxin oxidoreductase (PFOR) system, which operates at a low redox potential capable of reducing the nitro group of these drugs into cytotoxic radical intermediates (NCBI, 2023). Once activated, these radicals interact directly with the microbial DNA, causing extensive strand breakage and destabilization of the double helix, which effectively halts DNA replication and transcription (PubMed, 2018). This mechanism is highly selective for anaerobic bacteria (e.g., Bacteroides, Clostridium) and certain protozoa (e.g., Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica) because aerobic host cells lack the necessary reductive environment to activate the prodrug. Consequently, the target allows for potent antimicrobial activity with a high therapeutic index in humans. Resistance can occur through the expression of nim genes, which encode nitroreductases that convert the drug into non-toxic derivatives, preventing DNA damage (StatPearls, 2023).

Other names

Microbial DNAAnaerobic DNAProtozoan DNABacterial DNA

Nitroimidazole drugs act as prodrugs that enter the cell via passive diffusion and undergo reductive activation by the pyruvate:ferredoxin oxidoreductase (PFOR) system or similar electron transport proteins found in anaerobic environments. This reduction generates short-lived, highly reactive nitro radical anions and other reactive oxygen species that cause direct oxidative damage to the DNA, leading to strand breakage, loss of helical structure, and the inhibition of nucleic acid synthesis (StatPearls, 2023; PubChem, 2024).